Meeting
2019 Gastrointestinal Cancers Symposium
Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.
Authors
Yoshito Komatsu
Division of Cancer Chemotherapy, Hokkaido University Hospital, Sapporo, Japan
Yoshito Komatsu , Takeshi Kato , Yoshinori Kagawa , Takayuki Yoshino , Yasutoshi Kuboki , Makio Gamoh , Hirofumi Yasui , Kentaro Yamazaki , Hironaga Satake , Masahiro Goto , Hiroaki Tanioka , Eiji Oki , Masahito Kotaka , Akitaka Makiyama , Tadamichi Denda , Junpei Soeda , Kazunori Shibuya , Masaru Iwata , Koji Oba , Kensei Yamaguchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02613221
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 624)
DOI
10.1200/JCO.2019.37.4_suppl.624
Abstract #
624
Poster Bd #
K9
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A phase I/II study for panitumumab combined with TAS-102 in patients with RAS wild-type metastatic colorectal cancer (APOLLON study): Phase I results.
First Author: Takeshi Kato
Poster
2021 Gastrointestinal Cancers Symposium
PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
First Author: John H. Strickler
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji
Poster
2017 Gastrointestinal Cancers Symposium
A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
First Author: Patrick McKay Boland